南新制药拟不超4.8亿元收购未来医药所持标的资产组 丰富公司产品管线

Core Viewpoint - The company, Nanxin Pharmaceutical (688189.SH), has signed a purchase intention agreement to acquire a group of assets from Future Medicine for a cash consideration of up to 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection solutions [1][2] Group 1 - The acquisition will include the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with associated R&D and production technical materials, trademarks, patents, customer data, and regulatory approvals [1] - This transaction is expected to constitute a significant asset restructuring as defined by the regulations governing listed companies, and it will not involve the issuance of new shares or result in a change of control for the company [1] - The acquisition aligns with the company's strategy to enhance its product pipeline and optimize its product layout in the "anti-infection - chronic disease - nutritional support" categories, supporting its broader "healthcare" development strategy [1] Group 2 - The asset group includes a well-established national sales channel and academic promotion system, which will help the company expand new sales channels for its products and significantly enhance market access and coverage for its pediatric anti-influenza medications [2]